Dedov I I, Abugova I A, Shishko P I, Shamkhalova M Sh
Probl Endokrinol (Mosk). 1993 Jan-Feb;39(1):3-7.
A total of 40 patients with type I diabetes mellitus, in whom the disease was diagnosed 1 to 12 months previously, were examined. An imbalance between the T and B cellular components of the immunity was found in the patients with the early stages of the disease, as was an elevated titer of the complement C1 component as against the reference group. The degree of the immunologic shifts was in direct correlation with the HLA A9 antigen expression, this relationship being the most marked in cases with the HLA DR3 and DR4. The incidence of these antigens expression was significantly higher in the patients with marked immunity shifts, than in those with negligible immunity changes. Therapy with an immunosuppressant azathioprine was associated with a noticeable reduction of the initially elevated cellular immunity parameters (total T and B lymphocyte counts, T helpers-inductors, DR carriers) and a trend towards a reduction of all the components and total activity of the classical route of the complement activation predominantly at the expense of the C1 and C5 components. The efficacy of this drug in therapy of new cases of insulin-dependent diabetes mellitus was confirmed, and the indisputable relationship between the efficacy of immunity suppression, that helped achieve a clinical remission, and the disease duration, was demonstrated. Monitoring of the cellular and humoral immunity parameters, of the activity of the classical route of the complement activation permitted an indirect judgement on the usefulness of immunity suppression for the correction of immunity disorders as factors contributing to the development of microvascular disturbances in insulin-dependent diabetes mellitus.
共检查了40例I型糖尿病患者,这些患者在1至12个月前被诊断出患有该疾病。在疾病早期患者中发现免疫的T细胞和B细胞成分失衡,且与参照组相比补体C1成分滴度升高。免疫变化程度与HLA A9抗原表达直接相关,这种关系在HLA DR3和DR4病例中最为明显。这些抗原表达的发生率在免疫变化明显的患者中显著高于免疫变化可忽略不计的患者。使用免疫抑制剂硫唑嘌呤进行治疗与最初升高的细胞免疫参数(总T和B淋巴细胞计数、T辅助诱导细胞、DR携带者)明显降低相关,并且主要以C1和C5成分为代价,经典补体激活途径的所有成分和总活性有降低趋势。证实了该药物在胰岛素依赖型糖尿病新病例治疗中的疗效,并证明了有助于实现临床缓解的免疫抑制疗效与病程之间无可争议的关系。监测细胞和体液免疫参数、经典补体激活途径的活性,可以间接判断免疫抑制对纠正免疫紊乱的有用性,而免疫紊乱是导致胰岛素依赖型糖尿病微血管病变发展的因素。